Monday, April 09, 2012

AstraZeneca faces calls for shake-up : FT


Some of the biggest investors in AstraZeneca are calling for a radical shake-up of the board and executive team, as a new chairman prepares to join the underperforming Anglo-Swedish pharmaceutical group.

With the company trading on the lowest price/earnings multiple in the sector, some large shareholders have been lobbying to replace David Brennan as chief executive and push for a fresh business strategy.

Posted via email from Jack's posterous

No comments: